Formulation of Inhalation Medicines

Traini, Daniela; Young, Paul M.

doi:10.1002/9781118397145.ch3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2021

Publication Types

Select...

Article3

Other1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dry powder inhalation has been advocated as the choice of pulmonary drug delivery as a solid product is characterized by a high physicochemical quality [8]. Nonetheless, the delivery of nanocarrier via dry powder inhalation is limited by their submicron size.…”

mentioning

confidence: 99%

Choice of nanocarrier for pulmonary delivery of cancer therapeutics

Wong

2019

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

mentioning

confidence: 99%

Choice of nanocarrier for pulmonary delivery of cancer therapeutics

Wong

2019

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Pyrrolidone and Caprolactam‐Based Materials in Active Pharmaceutical Ingredient (API) Applications

Hood

Ananthraman²,

Musa

2021

Handbook of Pyrrolidone and Caprolactam Based Materials

View full text Add to dashboard Cite

Active pharmaceutical ingredients (APIs) are the essential, active ingredients of pharmaceutical dosage forms and drug delivery systems. This chapter provides a comprehensive and systematic coverage of pharmaceutical and biomedical applications of pyrrolidone and caprolactam‐based materials in API applications. Antibiotics and antimicrobials are indispensable drugs for human and animal health and well‐being. The chapter also provides an explanation of the mechanism of action for the excipients in dosage forms ranging from conventional solids and liquids to novel solids and colloidal drug delivery systems. The modulation of solubility of poorly soluble drugs is a viable and safe approach for enhancing the drug's bioavailability. The drug development within the pharmaceutical industry has undergone a significant transformation. Prior to the late 1980s, drug candidates were primarily established by empirically‐based screening programs, where the leading candidates were mostly selected from chemical compounds that had already undergone significant technical investigation.

show abstract